Skip to main content

Compare
Sotyktu vs. Skyrizi

Head-to-head comparisons of medication uses, side effects, warnings, and more.

Key takeaways

Sotyktu (deucravacitinib) and Skyrizi (risankizumab) are both medications used to treat moderate-to-severe plaque psoriasis in adults. However, they belong to different medication classes and have important differences. Sotyktu is a tyrosine kinase 2 (TYK2) inhibitor taken orally once a day. It works by blocking a protein that causes inflammation. On the other hand, Skyrizi is an interleukin antagonist administered as an injection every 2 or 3 months after initial doses. It blocks proteins involved in inflammation, called interleukin-23 (IL-23). Skyrizi is also FDA-approved for psoriatic arthritis, ulcerative colitis, and Crohn's disease, while Sotyktu is only approved for plaque psoriasis. Both medications can increase the risk of an infection, including an upper respiratory infection. These medications are only available in a branded version.

Sotyktu

(deucravacitinib)

Get free coupons

Skyrizi

(risankizumab)

Get free coupons

Summary for Sotyktu

Prescription only

Sotyktu (deucravacitinib) is used to treat plaque psoriasis and psoriatic arthritis in adults. It works as a tyrosine kinase 2 inhibitor to lessen inflammation. This medication comes as a tablet that you take once a day, with or without food. Side effects include a higher risk of infections, like upper respiratory infections. Sotyktu (deucravacitinib) is only available as a brand-name medication.

Indications for Sotyktu

Pros and Cons for Sotyktu

Pros

  • Taken by mouth once a day
  • Can take with or without food
  • Safe to take if you have kidney problems or mild-to-moderate liver problems

Cons

  • Can raise the risk of infections
  • Might need blood work done every so often to check for side effects
  • Not approved for children

Common Side Effects for Sotyktu

Warnings for Sotyktu

  • Allergic reactions
  • Risk of infections
  • Muscle damage
  • Liver damage
  • Possible risk of cancer

Summary for Skyrizi

Prescription only

Skyrizi (risankizumab or risankizumab-rzaa) is an injection used to treat different inflammatory conditions in adults. This includes plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It belongs to the drug class called interleukin antagonists. It works to lower inflammation and relieve symptoms. After the first few doses, you usually get the Skyrizi (risankizumab) injection every 2 or 3 months. This medication can raise your risk of infection as a side effect.

Indications for Skyrizi

Pros and Cons for Skyrizi

Pros

  • Given every 2 or 3 months after a couple of starter doses (depends on your condition)
  • Can give injections under the skin at home after you get trained

Cons

  • Must be given as an injection
  • Not approved for children

Common Side Effects for Skyrizi

Warnings for Skyrizi

  • Allergic reaction
  • Risk of infection
  • Rare case of liver injury
  • Caution when getting vaccines

Prices with our coupons for Sotyktu vs. Skyrizi

Price Card Drug Icon
Sotyktu30 tablets / 6mg
--
Get free coupons
More Information
Price Card Drug Icon
Skyrizi1 package / 1 pen of 150mg/ml
$20,217.99-
Get free coupons
More Information

Compare other Plaque Psoriasis and Psoriatic Arthritis drugs

Sotyktu vs. OtezlaSotyktu vs. SkyriziDuobrii vs. SkyriziDupixent vs. AdbryDupixent vs. Fasenra
Dupixent vs. SymbicortEntyvio vs. SkyriziMethotrexate vs. OtezlaOmvoh vs. SkyriziOmvoh vs. StelaraOtezla vs. CosentyxOtezla vs. EnbrelOtezla vs. HumiraRinvoq vs. OtezlaRinvoq vs. SkyriziSkyrizi vs. BimzelxSkyrizi vs. CosentyxSkyrizi vs. DupixentSkyrizi vs. EnbrelSkyrizi vs. HumiraSkyrizi vs. IlumyaSkyrizi vs. OtezlaSkyrizi vs. RemicadeSkyrizi vs. SimponiSkyrizi vs. TaltzStelara vs. SkyriziTaltz vs. OtezlaTremfya vs. OtezlaTremfya vs. SkyriziXeljanz vs. Otezla

Browse medications by letter

Show All

Browse prescription and over-the-counter medications from A to Z, compare drug prices, and start saving.